
FDA announced that clopidogrel, an antiplatelet agent given to reduce the risk of heart attack, unstable angina, stroke, and cardiovascular death in patients with cardiovascular disease, will require a new black-box warning about its reduced effectiveness in patients who are poor metabolizers of the drug.